Secukinumab for rheumatology: development and its potential place in therapy.

After the first-in-man study with secukinumab already demonstrating highly significant effects on psoriasis severity, 84 a Phase II, randomized, double-blind, placebo-controlled trial was performed on 125 patients with moderate-to-severe plaque psoriasis. 85 Subcutaneous injections with secukinumab at 4-week intervals resulted in significantly higher PASI75 scores, indicating at leas

also in 132,142 other papers

However, these differences did not reach statistical significance, thereby failing to show clinical efficacy for secukinumab in RA.

also in 111,027 other papers